CJC-1295 (without DAC) vs CJC-1295 + Ipamorelin

CJC-1295 (without DAC)

CJC-1295 without DAC, also called modified GRF (1-29), is a 29-residue synthetic analogue of growth hormone-releasing hormone (GHRH). Native GHRH has 44 residues, but its first 29 carry the receptor-binding activity, and this peptide is built on that shortened sequence with four amino-acid substitutions intended to slow breakdown. The name causes confusion: CJC-1295 originally referred to a version carrying a drug affinity complex (DAC), a reactive linker that binds albumin and greatly prolongs circulation. The form described here lacks that linker. Human studies of the DAC version exist but are few; published work on the form without DAC is thinner still, and much of what is said about it is inferred from the parent hormone.

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is one preparation holding two separate compounds, a GHRH analogue and a growth hormone secretagogue. Each component has a published literature of its own and a profile of its own on this site. The blend itself has none. No controlled study of the two given together was located. The nearest published work is a 2013 analytical paper describing a method that detects both, among seven peptides, in horse plasma, and a set of recent review articles that list them side by side. Every citation here is attributed to one component or the other.

How CJC-1295 (without DAC) acts

Like native GHRH, the peptide has been reported to bind the GHRH receptor, a class B G protein-coupled receptor on somatotroph cells of the anterior pituitary. Receptor activation couples to Gs, raising intracellular cAMP and releasing stored growth hormone; circulating growth hormone in turn drives IGF-1 production, mainly in the liver. The substitutions, D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27, were chosen to resist cleavage by dipeptidyl peptidase-4 and to reduce deamidation and oxidation at vulnerable residues. Without the albumin-binding linker its half-life is short, and pharmacokinetic data specific to this form are sparse.

How CJC-1295 + Ipamorelin acts

The two components act at different receptors. CJC-1295 is a modified analogue of growth hormone-releasing hormone; a 2006 randomised, placebo-controlled trial in healthy adults reported sustained rises in growth hormone and IGF-1 after a long-acting form of it. Ipamorelin is a pentapeptide that releases growth hormone through the growth hormone secretagogue receptor rather than the GHRH receptor, and its 1998 description in rat pituitary cells, rats and swine reported release without the rise in ACTH and cortisol seen with GHRP-6 and GHRP-2. Nothing published describes what the two do together.

The records side by side

• Type: CJC-1295 (without DAC), GHRH analog (Modified GRF 1-29); CJC-1295 + Ipamorelin, Two-peptide blend
• Molecular weight: CJC-1295 (without DAC), 3647.2 g/mol; CJC-1295 + Ipamorelin, not recorded
• Molecular formula: CJC-1295 (without DAC), C165H269N47O46; CJC-1295 + Ipamorelin, not recorded

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.